No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
AGEN240621C17000
- 0.91
- -0.19-17.27%
15min DelayClose May 31 15:59 ET
1.50High0.91Low
1.40Open1.10Pre Close4 Volume89 Open Interest17.00Strike Price511.00Turnover126.31%IV16.63%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier18DDays to Expiry0.91Time Value100Contract SizeAmericanOptions Type0.4499Delta0.0878Gamma12.07Leverage Ratio-0.0487Theta0.0030Rho5.43Eff Leverage0.0141Vega
Intraday
- 5D
- 1D
News
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of Agenus' Board of Directors granted
B.Riley Financial Maintains Agenus(AGEN.US) With Buy Rating, Maintains Target Price $42
B.Riley Financial analyst Mayank Mamtani maintains $Agenus(AGEN.US)$ with a buy rating, and maintains the target price at $42.According to TipRanks data, the analyst has a success rate of 26.2% and a
Buy Rating Affirmed for Agenus Amid Promising Colorectal Cancer Study Results
H.C. Wainwright Maintains Agenus(AGEN.US) With Buy Rating, Maintains Target Price $40
H.C. Wainwright analyst Emily Bodnar maintains $Agenus(AGEN.US)$ with a buy rating, and maintains the target price at $40.According to TipRanks data, the analyst has a success rate of 38.3% and a tota
Analysts Offer Insights on Healthcare Companies: Agenus (AGEN), Merus (MRUS) and Iovance Biotherapeutics (IOVA)
Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, and Robin Taylor, Chief Commercial
Comments
So $Agenus(AGEN.US$ owner bought shares at some low price at 0.6, then the price went down to 0.3 then reverse split.
Now the price is $15.00. Sometimes things get worse before it get better.
You could be a day trader and make your profit or cut losses or an investor and hold on.
I see some possibilities in this company and reverse split is to consolidate compliance. Now the ethics of the management or if they consider investor or shareholder investment is another d...
Now the price is $15.00. Sometimes things get worse before it get better.
You could be a day trader and make your profit or cut losses or an investor and hold on.
I see some possibilities in this company and reverse split is to consolidate compliance. Now the ethics of the management or if they consider investor or shareholder investment is another d...
2
$Agenus(AGEN.US$ Reuters· 5 mins ago
FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/Bal Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/Bal Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
$Agenus(AGEN.US$ I knew the momentum wouldn't last.
Read more